Glanbia will publish interim results this Wednesday, which will be its first set of results under the new segmental structure.
In May, the company announced it was reorganising its US Cheese & Global Nutritionals division into two business segments called Global Performance Nutrition and Global Ingredients.
During the month, Glanbia described overall group trading as solid, with management reiterating guidance of 8-10 per cent growth in adjusted earning per share on a constant currency basis.
Revenue for US Cheese & Global Nutritionals for the first four months of the year grew 14 per cent compared to the first four months of 2012. The acquisition of Aseptic Solutions, which was completed in July 2012, added 2 per cent to revenue growth.
Davy Stockbrokers says it expects the August interims to deviate little from the May interims in tone and trend, with global dairy prices remaining resilient.
The stockbroking firm has forecast group ebita to increase by 8.5 per cent to €190.8 million, adding that this week’s interims may provide commentary on Glanbia’s internal investment programme, the new capacity expansion in Aurora Illinois for Global Performance Nutrition and the new cheese innovation centre in Idaho .
MusclePharm, a peer of Glanbia’s Optimum Nutrition, last week reported gross revenues of $28.5 million, which represents year-on-year sales growth of 51 per cent for the second quarter of the year.
